Influence of the Circadian Timing System on Tacrolimus Pharmacokinetics and Pharmacodynamics After Kidney Transplantation

被引:14
|
作者
Fontova, Pere [1 ,2 ,3 ]
Colom, Helena [4 ]
Rigo-Bonnin, Raul [2 ,5 ]
van Merendonk, Lisanne N. [1 ,2 ,3 ]
Vidal-Alabro, Anna [1 ,2 ,3 ]
Montero, Nuria [1 ,2 ,3 ]
Melilli, Edoardo [1 ,2 ,3 ]
Meneghini, Maria [1 ,2 ,3 ]
Manonelles, Anna [1 ,2 ,3 ]
Cruzado, Josep M. [1 ,2 ,3 ]
Torras, Juan [1 ,2 ,3 ]
Grinyo, Josep Maria [1 ,2 ,3 ]
Bestard, Oriol [1 ,2 ,3 ]
Lloberas, Nuria [1 ,2 ,3 ]
机构
[1] Bellvitge Univ Hosp, Nephrol Dept, Barcelona, Spain
[2] Inst Invest Biomed Bellvitge, Nephrol & Transplantat, Barcelona, Spain
[3] Univ Barcelona, Dept Clin Sci, Barcelona, Spain
[4] Univ Barcelona, Sch Pharm, Dept Pharm & Pharmaceut Technol, Biopharmaceut & Pharmacokinet Unit, Barcelona, Spain
[5] Univ Bellvitge, Bellvitge Univ Hosp, Biochem Dept, Inst Invest Biomed Bellvitge, Barcelona, Spain
关键词
tacrolimus; pharmacodynamic; pharmacokinetics; circadian rhythm; kidney transplantation; immunosuppression; BLOOD MONONUCLEAR-CELLS; MULTIDRUG-RESISTANCE GENE; CYCLOSPORINE; LIVER; METABOLISM; ABSORPTION; CHRONOPHARMACOKINETICS; PHARMACOGENETICS; POLYMORPHISMS; EXPRESSION;
D O I
10.3389/fphar.2021.636048
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Tacrolimus is the backbone immunosuppressant after solid organ transplantation. Tacrolimus has a narrow therapeutic window with large intra- and inter-patient pharmacokinetic variability leading to frequent over- and under-immunosuppression. While routine therapeutic drug monitoring (TDM) remains the standard of care, tacrolimus pharmacokinetic variability may be influenced by circadian rhythms. Our aim was to analyze tacrolimus pharmacokinetic/pharmacodynamic profiles on circadian rhythms comparing morning and night doses of a twice-daily tacrolimus formulation. Methods: This is a post-hoc analysis from a clinical trial to study the area under curve (AUC) and the area under effect (AUE) profiles of calcineurin inhibition after tacrolimus administration in twenty-five renal transplant patients. Over a period of 24 h, an intensive sampling (0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 12.5, 13, 13.5, 14, 15, 20, and 24 h) was carried out. Whole blood and intracellular tacrolimus concentrations and calcineurin activity were measured by UHPLC-MS/MS. Results: Whole blood and intracellular AUC(12-24 h) and C-max achieved after tacrolimus night dose was significantly lower than after morning dose administration (AUC(0-12 h)) (p < 0.001 for both compartments). AUE(0-12 h) and AUE(12-24 h) were not statistically different after morning and night doses. Total tacrolimus daily exposure (AUC(0-24 h)), in whole blood and intracellular compartments, was over-estimated when assessed by doubling the morning AUC(0-12 h) data. Conclusion: The lower whole blood and intracellular tacrolimus concentrations after night dose might be influenced by a distinct circadian clock. This significantly lower tacrolimus exposure after night dose was not translated into a significant reduction of the pharmacodynamic effect. Our study may provide conceptual bases for better understanding the TDM of twice-daily tacrolimus formulation.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Wuzhi capsule and haemoglobin influence tacrolimus elimination in paediatric kidney transplantation patients in a population pharmacokinetics analysis: A retrospective study
    Wang, Dong-Dong
    Chen, Xiao
    Li, Zhi-Ping
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2019, 44 (04) : 611 - 617
  • [42] Factors affecting the pharmacokinetics of tacrolimus in the first year after renal transplantation
    Undre, NA
    Schäfer, A
    TRANSPLANTATION PROCEEDINGS, 1998, 30 (04) : 1261 - 1263
  • [43] Pretransplant pharmacokinetics: Does it predict the dose of tacrolimus after renal transplantation?
    Boots, JMM
    Christiaans, MHL
    Undre, NA
    van Hooff, JP
    TRANSPLANTATION PROCEEDINGS, 2002, 34 (08) : 3171 - 3172
  • [44] INFLUENCE OF DONOR RELATED FACTORS ON OUTCOMES WITH TACROLIMUS-BASED IMMUNOSUPPRESSION AFTER KIDNEY TRANSPLANTATION - THE OSAKA STUDY (OPTIMIZING IMMUNOSUPPRESSION AFTER KIDNEY TRANSPLANTATION WITH Advagraf®
    Lehner, Frank
    Banas, Bernhard
    Kamar, Nassim
    Glyda, Maciej
    Viklicky, Ondrej
    Albano, Laetitia
    TRANSPLANT INTERNATIONAL, 2011, 24 : 164 - 165
  • [45] Tacrolimus related neurologic complication after pediatric kidney transplantation
    Kwun, Woo-Hyung
    JOURNAL OF THE KOREAN SURGICAL SOCIETY, 2011, 81 (03): : 225 - 228
  • [46] Bilateral Blindness Owing to Tacrolimus Vasculopathy after Kidney Transplantation
    Toro, Mario D.
    Avitabile, Teresio
    Reibaldi, Michele
    OPHTHALMOLOGY RETINA, 2019, 3 (03): : 285 - 285
  • [47] Effect of cyclosporin and tacrolimus on the oxidation of lipoproteins after kidney transplantation
    Castelao, AM
    Ramos, R
    Serón, D
    Gil-Vernet, S
    Fiol, C
    Gómez-Gerique, N
    Yzaguirre, MT
    Hurtado, I
    Sabaté, I
    Alsina, J
    Grinyó, JM
    NEFROLOGIA, 2002, 22 (04): : 364 - 369
  • [48] Severe tacrolimus-induced parkinsonism after kidney transplantation
    Riemersma, N.
    Kremer, D.
    Prak, R.
    Huser, F.
    vander Stouwe, M.
    Vroomen, C.
    Bakker, S.
    MOVEMENT DISORDERS, 2023, 38 : S252 - S252
  • [49] Successful conversion from tacrolimus to cyclosporine after kidney transplantation
    Yashima, J
    Koyama, I
    Ishida, H
    Sawada, T
    Tojimbara, T
    Nakajima, I
    Fuchinoue, S
    Agishi, T
    TRANSPLANTATION PROCEEDINGS, 2000, 32 (07) : 1693 - 1693
  • [50] Tacrolimus and quality of life after kidney transplantation - a multicenter study
    Bohlke, M
    Rocha, M
    Gomes, RH
    Marini, SS
    Terhorst, L
    Barcellos, FC
    Hallal, PC
    Casarini, D
    Irigoyen, MC
    CLINICAL TRANSPLANTATION, 2006, 20 (04) : 504 - 508